{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:34:09Z","timestamp":1793126049511,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejps.2026.107686","type":"journal-article","created":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:37:59Z","timestamp":1791729479000},"page":"107686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Engineering nanocarriers for PROTAC delivery: liposomes, cyclodextrin aggregates, and albumin-based nanoparticles for ACBI2 and ACBI3"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4731-8161","authenticated-orcid":false,"given":"Miriam","family":"Jaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5967-0834","authenticated-orcid":false,"given":"Luca","family":"Dari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"K\u00f6ll-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4523-8061","authenticated-orcid":false,"given":"Anne","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1314-8383","authenticated-orcid":false,"given":"Jan","family":"Lembeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurine","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6886-0857","authenticated-orcid":false,"given":"Bizan N.","family":"Balzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-460X","authenticated-orcid":false,"given":"Regine","family":"S\u00fcss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107686_bib0001","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1021\/acs.molpharmaceut.5c01070","article-title":"Degraders on demand: engineering smart nanocarriers for PROTAC delivery","volume":"23","author":"Amalraj","year":"2026","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107686_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118352","article-title":"Liposomal formulation of the CDK9 PROTAC THAL-SNS-032 enhances the antitumor activity in breast cancer cell lines","volume":"189","author":"Arenas-Moreira","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2026.107686_bib0003","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsmedchemlett.0c00556","article-title":"Solution conformations shed light on PROTAC cell permeability","volume":"12","author":"Atilaw","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2026.107686_bib0004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2026.107686_bib0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic \u2014 a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejps.2026.107686_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040728","article-title":"Emerging albumin-binding anticancer drugs for tumor-targeted drug delivery: current understandings and clinical translation","volume":"14","author":"Cho","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107686_bib0007","doi-asserted-by":"crossref","first-page":"115","DOI":"10.64719\/pb.4397","article-title":"Brexanolone to treat postpartum depression in adult women","volume":"51","author":"Cornett","year":"2025","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.ejps.2026.107686_bib0008","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/acs.jmedchem.7b00717","article-title":"Beyond the rule of 5: lessons learned from AbbVie\u2019s drugs and compound collection: miniperspective","volume":"61","author":"DeGoey","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2026.107686_bib0009","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1593\/tlo.09109","article-title":"SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients","volume":"2","author":"Desai","year":"2009","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejps.2026.107686_bib0011","unstructured":"European Medicines Agency (EMA), 2017. Cyclodextrins used as excipients (EMA\/CHMP\/495747\/2013)."},{"key":"10.1016\/j.ejps.2026.107686_bib0010","unstructured":"European Medicines Agency (EMA), 2023. ICH Q2(R2) guideline on validation of analytical procedures."},{"key":"10.1016\/j.ejps.2026.107686_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17030350","article-title":"Albumin-based nanoparticles with factorial design as a promising approach for remodeled repaglinide: evidence from In Silico, In Vitro, and In Vivo Evaluations","volume":"17","author":"Faisal","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107686_bib0013","unstructured":"FDA, 2026. NDA 219835 approval."},{"key":"10.1016\/j.ejps.2026.107686_bib0014","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1208\/ps050432","article-title":"Pharmacokinetics of paclitaxel-containing liposomes in rats","volume":"5","author":"Fetterly","year":"2003","journal-title":"AAPS PharmSci."},{"key":"10.1016\/j.ejps.2026.107686_bib0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3109\/08982104.2012.742537","article-title":"Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution","volume":"23","author":"Flaten","year":"2013","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2026.107686_bib0016","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1021\/acsmedchemlett.9b00597","article-title":"PROTAC technology: opportunities and challenges","volume":"11","author":"Gao","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejps.2026.107686_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2021.119489","article-title":"The albumin-based nanoparticle formation in relation to protein aggregation","volume":"252","author":"Ghadami","year":"2021","journal-title":"Spectrochim. Acta. A. Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ejps.2026.107686_bib0018","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2017.07.047","article-title":"Dual centrifugation \u2013 a new technique for nanomilling of poorly soluble drugs and formulation screening by an DoE-approach","volume":"530","author":"Hagedorn","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107686_bib0019","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.sbi.2021.06.013","article-title":"Stopping the beating heart of cancer: KRAS reviewed","volume":"71","author":"Herdeis","year":"2021","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejps.2026.107686_bib0020","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jconrel.2016.04.031","article-title":"Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release \u2212\/transfer-assay","volume":"232","author":"Hinna","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2026.107686_bib0021","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1073\/pnas.1316793111","article-title":"Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers","volume":"111","author":"Hoffman","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejps.2026.107686_bib0022","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41581-022-00601-z","article-title":"Cellular senescence: the good, the bad and the unknown","volume":"18","author":"Huang","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejps.2026.107686_bib0023","article-title":"A DoE-dual centrifugation-driven screening platform for liposomal incorporation of poorly soluble APIs: application to the PROTAC ACBI2","volume":"12","author":"Jaki","year":"2026","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107686_bib0024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/1061186X.2023.2185247","article-title":"Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 in vivo","volume":"31","author":"Jiang","year":"2023","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2026.107686_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15020706","article-title":"Tailoring the lamellarity of liposomes prepared by dual centrifugation","volume":"15","author":"Koehler","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107686_bib0026","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33430-6","article-title":"A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo","volume":"13","author":"Kofink","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2026.107686_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082098","article-title":"Development of liposome systems for enhancing the PK properties of bivalent PROTACs","volume":"15","author":"Kou","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107686_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2020.105837","article-title":"SpheroidJ: an open-source set of tools for spheroid segmentation","volume":"200","author":"Lacalle","year":"2021","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.ejps.2026.107686_bib0029","series-title":"Albumin-stabilisierte Und Liposomale Mitotan-Nanopartikel Zur Therapie Des Nebennierenrindenkarzinoms","author":"Langer","year":"2023"},{"key":"10.1016\/j.ejps.2026.107686_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14091891","article-title":"Mitotane nanocarriers for the treatment of adrenocortical carcinoma: evaluation of albumin-stabilized nanoparticles and liposomes in a preclinical In vitro study with 3D spheroids","volume":"14","author":"Langer","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107686_bib0031","doi-asserted-by":"crossref","DOI":"10.2310\/7290.2008.00023","article-title":"Optimizing imaging of three-dimensional multicellular tumor spheroids with fluorescent reporter proteins using confocal microscopy","volume":"7","author":"Le Roux","year":"2008","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.ejps.2026.107686_bib0032","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/2472630318756058","article-title":"Quantitative live-cell confocal imaging of 3D spheroids in a high-throughput format","volume":"23","author":"Leary","year":"2018","journal-title":"SLAS Technol."},{"key":"10.1016\/j.ejps.2026.107686_bib0033","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2026.107686_bib0034","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-022-00112-0","article-title":"An overview of PROTACs: a promising drug discovery paradigm","volume":"3","author":"Liu","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ejps.2026.107686_bib0035","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1002\/jps.23077","article-title":"Cyclodextrins as functional excipients: methods to enhance complexation efficiency","volume":"101","author":"Loftsson","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107686_bib0036","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1177\/1087057103256465","article-title":"Technical notes: a simple technique for reducing edge effect in cell-based assays","volume":"8","author":"Lundholt","year":"2003","journal-title":"SLAS Discov."},{"key":"10.1016\/j.ejps.2026.107686_bib0037","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2026.107686_bib0038","doi-asserted-by":"crossref","DOI":"10.1038\/s43246-026-01073-5","article-title":"Engineering the biophysical properties of lipid nanostructures for drug delivery","volume":"7","author":"Menge","year":"2026","journal-title":"Commun. Mater."},{"key":"10.1016\/j.ejps.2026.107686_bib0039","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijpharm.2009.11.035","article-title":"Self-assembled cyclodextrin aggregates and nanoparticles","volume":"387","author":"Messner","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107686_bib0040","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0378-5173(03)00265-5","article-title":"Ternary systems of naproxen with hydroxypropyl-\u03b2-cyclodextrin and aminoacids","volume":"260","author":"Mura","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2026.107686_bib0041","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0005-2736(79)90234-7","article-title":"Transfer of cholesterol between liposomal membranes","volume":"553","author":"Nakagawa","year":"1979","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"10.1016\/j.ejps.2026.107686_bib0042","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2478\/s11534-011-0096-2","article-title":"Gwyddion: an open-source software for SPM data analysis","volume":"10","author":"Ne\u010das","year":"2012","journal-title":"Open Phys."},{"key":"10.1016\/j.ejps.2026.107686_bib0043","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nrd3554","article-title":"Interfering with pH regulation in tumours as a therapeutic strategy","volume":"10","author":"Neri","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejps.2026.107686_bib0044","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1021\/acsomega.0c02879","article-title":"Head-to-Head comparison of the penetration efficiency of lipid-based nanoparticles into tumor spheroids","volume":"5","author":"Niora","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejps.2026.107686_bib0045","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020272","article-title":"PEGylated versus non-PEGylated pH-sensitive liposomes: new insights from a comparative antitumor activity study","volume":"14","author":"Nunes","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2026.107686_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202501384","article-title":"Remodeling the physicochemical and pharmacokinetic properties of PROTAC via lipid nanodisks for cancer therapy","volume":"12","author":"Pan","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejps.2026.107686_bib0047","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10529-005-5803-x","article-title":"A pitfall of the 3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay due to evaporation in wells on the edge of a 96 well plate","volume":"27","author":"Patel","year":"2005","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.ejps.2026.107686_bib0048","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.ejps.2026.107686_bib0049","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0005-2736(93)90270-A","article-title":"The influence of size and composition on the cholesterol mobilizing properties of liposomes in vivo","volume":"1153","author":"Rodrigueza","year":"1993","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"10.1016\/j.ejps.2026.107686_bib0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14787210.2023.2170350","article-title":"Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential","volume":"21","author":"Russo","year":"2023","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.ejps.2026.107686_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2021.e08702","article-title":"Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy","volume":"8","author":"Saraswat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ejps.2026.107686_bib0052","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.ejps.2026.107686_bib0053","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/(SICI)1096-9888(199808)33:8<729::AID-JMS687>3.0.CO;2-U","article-title":"Study of \u03b2-cyclodextrin-ketoconazole-tartaric acid multicomponent non-covalent association by positive and negative ionspray mass spectrometry","volume":"33","author":"Selva","year":"1998","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ejps.2026.107686_bib0054","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","article-title":"The uniqueness of albumin as a carrier in nanodrug delivery","volume":"18","author":"Spada","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2026.107686_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020486","article-title":"Functionalized liposome and albumin-based systems as carriers for poorly water-soluble anticancer drugs: an updated review","volume":"10","author":"Teixeira","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejps.2026.107686_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2026.107587","article-title":"Targeted polymeric nanoparticles enable epithelial translocation of PROTACs and preserve intracellular protein degradation activity","volume":"224","author":"Vogel-Kindgen","year":"2026","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107686_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2022.101512","article-title":"Nanoparticle-based medicines in clinical cancer therapy","volume":"45","author":"Wang","year":"2022","journal-title":"Nano Today"},{"key":"10.1016\/j.ejps.2026.107686_bib0058","doi-asserted-by":"crossref","DOI":"10.1091\/mbc.E23-05-0152","article-title":"CRISPR-mediated reversion of oncogenic KRAS mutation results in increased proliferation and reveals independent roles of Ras and mTORC2 in the migration of A549 lung cancer cells","volume":"34","author":"Werner","year":"2023","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejps.2026.107686_bib0059","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12020709","article-title":"KRAS mutations in solid tumors: characteristics, current therapeutic strategy, and potential treatment exploration","volume":"12","author":"Yang","year":"2023","journal-title":"J. Clin. Med."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726002605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:56:15Z","timestamp":1793123775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726002605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":59,"alternative-id":["S0928098726002605"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107686","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering nanocarriers for PROTAC delivery: liposomes, cyclodextrin aggregates, and albumin-based nanoparticles for ACBI2 and ACBI3","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107686","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107686"}}